FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
Yervoy delivers a surprise in liver cancer
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.
Astra’s radiopharma Fusion
AstraZeneca's quiet, cautious work is followed by a $2bn takeover.
Deal analysis part three – the undecided
Of the big oncology deals since 2016, there are still plenty that could go either way.
